NIDDM in the cat: treatment with the oral hypoglycemic medication, glipizide

Vet Clin North Am Small Anim Pract. 1995 May;25(3):599-615. doi: 10.1016/s0195-5616(95)50056-7.


The oral hypoglycemic medication, glipizide, provides a viable therapeutic alternative to conventional insulin therapy with a positive therapeutic response in approximately 50% of diabetic cats with non-insulin-dependent disease. Response to glipizide therapy or lack thereof usually is evident within the first 4 to 6 weeks of treatment. Adverse side effects occurred in less than 10% of patients. The existence of residual beta cell function is necessary for response to glipizide therapy. Predictors of response to glipizide therapy were not found. Identification and correction or control of existing insulin antagonistic disease processes, as well as, discontinuation of diabetogenic medications that may be contributing to insulin resistance is also important.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Administration, Oral
  • Animals
  • Cat Diseases / drug therapy*
  • Cat Diseases / etiology
  • Cats
  • Diabetes Mellitus, Type 2 / drug therapy
  • Diabetes Mellitus, Type 2 / etiology
  • Diabetes Mellitus, Type 2 / veterinary*
  • Glipizide / administration & dosage
  • Glipizide / adverse effects
  • Glipizide / therapeutic use*
  • Hypoglycemic Agents / administration & dosage
  • Hypoglycemic Agents / adverse effects
  • Hypoglycemic Agents / therapeutic use*


  • Hypoglycemic Agents
  • Glipizide